Cutaneous lupus erythematosus: updates on pathogenesis and associations with systemic lupus.
Cutaneous lupus erythematosus (CLE) is a common manifestation among systemic lupus patients. There are no U.S. Food and Drug Administration approved therapies for CLE, and these lesions are frequently disfiguring and refractory to treatment. The present review will cover the recent inroads made into understanding the mechanisms behind CLE lesions and discuss promising therapeutic developments.



The definition of cutaneous lupus is being refined to facilitate diagnostic and research protocols. Research into the pathogenesis of CLE is accelerating, and discoveries are now identifying genetic and epigenetic changes which may predispose to particular disease manifestations. Furthermore, unique features of disease subtypes are being defined. Murine work supports a connection between cutaneous inflammation and systemic lupus disease activity. Importantly, human trials of type I interferon blockade hold promise for improving our treatment armamentarium for refractory CLE lesions.



Continued research to understand the mechanisms driving CLE will provide new methods for prevention and treatment of cutaneous lesions. These improvements may also have important effects on systemic disease activity, and thus, efforts to understand this link should be supported.
aDivision of Rheumatology, Department of Internal Medicine bDivision of Rheumatology, Department of Pediatrics, University of Michigan, Ann Arbor, Michigan, USA.
Jasmine N
JN
Stannard
J Michelle
JM
Kahlenberg
D000279:Administration, Cutaneous; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000962:Antimalarials / Q000627:therapeutic use; D001323:Autoantibodies / Q000276:immunology*; D060908:CTLA-4 Antigen / Q000235:genetics; D016207:Cytokines / Q000276:immunology*; D019175:DNA Methylation; D003622:Dapsone / Q000627:therapeutic use; D044127:Epigenesis, Genetic; D005786:Gene Expression Regulation; D006680:HLA Antigens / Q000235:genetics; D006801:Humans; D006886:Hydroxychloroquine / Q000627:therapeutic use; D050835:Interferon Regulatory Factors / Q000235:genetics; D007370:Interferon Type I / Q000037:antagonists & inhibitors / Q000276:immunology*; D008178:Lupus Erythematosus, Cutaneous / Q000150:complications / Q000188:drug therapy / Q000235:genetics / Q000276:immunology*; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000276:immunology*; D011796:Quinacrine / Q000627:therapeutic use; D013473:Sunscreening Agents / Q000627:therapeutic use; D053634:TYK2 Kinase / Q000235:genetics; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics; D014466:Ultraviolet Rays / Q000009:adverse effects
D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000962:Antimalarials; D001323:Autoantibodies; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D016207:Cytokines; D006680:HLA Antigens; C431713:IRF5 protein, human; D050835:Interferon Regulatory Factors; D007370:Interferon Type I; D013473:Sunscreening Agents; C439524:TNF protein, human; D014409:Tumor Necrosis Factor-alpha; D006886:Hydroxychloroquine; D003622:Dapsone; D053634:TYK2 Kinase; C070139:TYK2 protein, human; D011796:Quinacrine; C502936:tocilizumab; C577244:rontalizumab; C568334:sifalimumab